Skip to main content
      RT @uptoTate: In clinic US guided entheseal biopsy? Abs 1025 at #ACR22 recommends the lateral epicondyle tendon plate in

      Dr. Rachel Tate uptoTate

      3 years 1 month ago
      In clinic US guided entheseal biopsy? Abs 1025 at #ACR22 recommends the lateral epicondyle tendon plate in PsA pts. @RheumNow https://t.co/VomyFkecLq
      RT @AurelieRheumo: Window of opportunity in PsA
      CorEvitas registry:

      Early initiators had more severe disease & wors

      Aurelie Najm AurelieRheumo

      3 years 1 month ago
      Window of opportunity in PsA CorEvitas registry: Early initiators had more severe disease & worse PROs but if DMARD therapy initiated within 1 yr: RR=2 MDA achievement & higher reduction of CDAI https://t.co/Xm9i7aiq85 Abs#1493 #ACR22 @Rheumnow https://t.co/RAGoHeuSIg
      RT @AurelieRheumo: Performance BASDAI & ASDAS in evaluating PsA axial symptoms?

      400+ pts DISCOVER 1&2
      Weak corr

      Aurelie Najm AurelieRheumo

      3 years 1 month ago
      Performance BASDAI & ASDAS in evaluating PsA axial symptoms? 400+ pts DISCOVER 1&2 Weak correlations w/ peripheral arthritis Moderate/strong correlations w/ fatigue & pain Both perform similarly but do they perform well enough? https://t.co/alnrEXtydp Abs#1037 #ACR22 @Rheumnow https://t.co/Zuf1FruneK
      RT @JulianSegan: Benefits with receiving anabolic agents upfront before antiresoprtives (as opposed to other way around)

      Julian Segan JulianSegan

      3 years 1 month ago
      Benefits with receiving anabolic agents upfront before antiresoprtives (as opposed to other way around). Shame about lack of access to this sequence currently @RheumNow #ACR22 #osteoporosis https://t.co/S2ttbrVaab
      RT @uptoTate: Low likelihood of syndesmophyte formation in PsA but is more likely assoc'd w/ axial involvement radiograp

      Dr. Rachel Tate uptoTate

      3 years 1 month ago
      Low likelihood of syndesmophyte formation in PsA but is more likely assoc'd w/ axial involvement radiographically + high CRP. Abs 1014 #ACR22 @RheumNow https://t.co/M5Tc0fd64s https://t.co/e25gwVQKeo
      RT @AurelieRheumo: DISCOVER 1 & 2: Subanalysis of GUS in 181 pts w/ Axial PsA and imaging confirmed SI

      GUS improves

      Aurelie Najm AurelieRheumo

      3 years 1 month ago
      DISCOVER 1 & 2: Subanalysis of GUS in 181 pts w/ Axial PsA and imaging confirmed SI GUS improves BASDAI, mBASDAI, spinal pain, morning stiffness, and ASDAS from W8 to W24 W24 Response rates BASDAI50 38% BASDAI70 20% https://t.co/MrS8atrIOI Abs#1035 #ACR22 @Rheumnow https://t.co/wMDkO1Qak9
      RT @doctorRBC: Most important point from the Great Debate on treating pre-RA.
      Are we really treating to prevent RA or a

      Robert B Chao, MD doctorRBC

      3 years 1 month ago
      Most important point from the Great Debate on treating pre-RA. Are we really treating to prevent RA or are we simply delaying RA onset? I don't think there is enough data to treat pre-clinical RA with our current arsenal of DMARDs. What would you do? @RheumNow #ACR22
      RT @doctorRBC: The Great Debate! Should you treat pre-clinical RA?
      ACPA+ ~40% did not convert to clinical RA
      RF+/ACPA+ l

      Robert B Chao, MD doctorRBC

      3 years 1 month ago
      The Great Debate! Should you treat pre-clinical RA? ACPA+ ~40% did not convert to clinical RA RF+/ACPA+ least likely to seroconvert to negative @RheumNow #ACR22 https://t.co/djVPKDdWjz
      RT @RHEUMarampa: Dr. Talabi: Progestin-only has⬇️thrombotic risk vs. estrogen👇
      ‼️Safety signal for DMPA/depo

      sheila RHEUMarampa

      3 years 1 month ago
      Dr. Talabi: Progestin-only has⬇️thrombotic risk vs. estrogen👇 ‼️Safety signal for DMPA/depo shot bec. might be more prothrombotic vs. other progestin methods; addt'l studies needed; recommend to avoid in aPL+ for now #ACR22 @Rheumnow https://t.co/pQe5H8wqvi
      RT @KDAO2011: "Less than 1 in 6 rheumatology guideline recommendations are informed by head-to-head RCTs." #ACR22 abst#1

      TheDaoIndex KDAO2011

      3 years 1 month ago
      "Less than 1 in 6 rheumatology guideline recommendations are informed by head-to-head RCTs." #ACR22 abst#1284 @rheumnow Comparative Effectiveness Randomized Controlled Trials in Rheumatology Guidelines https://t.co/l5NzzcHRSA
      RT @uptoTate: Most prevalent locations of enthesitis on the global SpA population are the lumbar spinous processes, the

      Dr. Rachel Tate uptoTate

      3 years 1 month ago
      Most prevalent locations of enthesitis on the global SpA population are the lumbar spinous processes, the thoracic spinous processes & Achilles tendon. MEI & MASES best capturing axSpA enthesitis. MEI & SPARCC best in pSpA & PsA. Abs 1004 #ACR22 @RheumNow https://t.co/6IbusqHI5d https://t.co/5y5NFthyJz
      RT @drdavidliew: Tofacitinib in new-onset PMR:
      Nice mechanistic data - all the right things line up - leading to promis

      David Liew drdavidliew

      3 years 1 month ago
      Tofacitinib in new-onset PMR: Nice mechanistic data - all the right things line up - leading to promising proof-of-concept study (EAST PMR) Plenty to tease apart here but real promise to explore in bigger studies ABST1107 #ACR22 @RheumNow https://t.co/s4ts7lrVtZ
      RT @RHEUMarampa: Dr Iyer shares how ROSCE can teach trainees #telerheumatology using video visits:
      ☝️ Relevant to ca

      sheila RHEUMarampa

      3 years 1 month ago
      Dr Iyer shares how ROSCE can teach trainees #telerheumatology using video visits: ☝️ Relevant to career, enhanced self-directed learning ☝️Accdg to ROSCE results, improvement needed on telemed focused exams 🤓Video ROSCE as T-L strat, eval #ACR22 @RheumNow #MedEd @rheumarhyme https://t.co/kZXMrbwtzW
      RT @JulianSegan: Coming off denosumab is very tricky! No such thing as drug holiday given high risk of rebound fractures

      Julian Segan JulianSegan

      3 years 1 month ago
      Coming off denosumab is very tricky! No such thing as drug holiday given high risk of rebound fractures. Need to cap with BP but duration uncertain. @RheumNow #ACR22 #osteoporosis https://t.co/a4VNAI2D49
      ×